Pfizer CEO Albert Bourla addresses a press conference after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.
John Thys | Pool | Reuters
Pfizer on Tuesday submitted its application to the Food and Drug Administration for emergency authorization of its Covid-19 treatment pill.
“We will submit as quickly as today,” Pfizer CEO Albert Bourla said during a conference hosted by STAT news earlier Tuesday. “I hope today we are submitting to the FDA.”
Pfizer’s pill, used in combination with an HIV drug, cut the risk of hospitalization from Covid by 89% in high-risk adults who were exposed to the virus, according to the company.
Bourla had previously said that Pfizer planned to submit its data to the FDA before Thanksgiving.
Earlier Tuesday, Pfizer announced that it would allow generic manufacturers to supply its antiviral pill, known as Paxlovid, to 95 low and middle-income countries.
This is breaking news. Please Check back for updates.
